Publications of Tanya Dogra

Pelz, L., Dogra, T., Marichal-Gallardo, P., Hein, M. D., Hemissi, G., Kupke, S. Y., Genzel, Y., & Reichl, U. (2024)Production of antiviral “OP7 chimera” defective interfering particles free of infectious virusApplied Microbiology and Biotechnology, 108, 1–15doi: 10.1007/s00253-023-12959-6.

Dogra, T., Pelz, L., Boehme, J. D., Küchler, J., Kershaw, O., Marichal-Gallardo, P., Baelkner, M., Hein, M. D., Gruber, A. D., Benndorf, D., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U. (2023)Generation of “OP7 chimera” defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in miceScientific Reports, 13, 20936doi: 10.1038/s41598-023-47547-1.

Hein, M. D., Kazenmaier, D., van Heuvel, Y., Dogra, T., Cattaneo, M., Kupke, S. Y., Stitz, J., Genzel, Y., & Reichl, U. (2023)Production of retroviral vectors in continuous high cell density cultureApplied Microbiology and Biotechnology, 107, 5947–5961doi: 10.1007/s00253-023-12689-9.

van Heuvel, Y., Schatz, S., Hein, M., Dogra, T., Kazenmaier, D., Tschorn, N., Genzel, Y., & Stitz, J. (2023)Novel suspension retroviral packaging cells generated by transposition using transposase encoding mRNA advance vector yields and enable production in bioreactorsFrontiers in Bioengineering and Biotechnology, 11, 1076524doi: 10.3389/fbioe.2023.1076524.

Pelz, L., Rüdiger, D., Dogra, T., Alnaji, F. G., Genzel, Y., Brooke, C. B., Kupke, S. Y., & Reichl, U. (2021)Semi-continuous propagation of influenza A virus and its defective interfering particles: analyzing the dynamic competition to select candidates for antiviral therapyJournal of Virology, 95 (24), e01174-21doi: 10.1128/JVI.01174-21.

Dogra, T., Pelz, L., Boehme, J. D., Baelkner, M., Kershaw, O., Marichal-Gallardo, P., Gruber, A. D., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccinationPresented at: 17^th Vaccine CongressGlasgow (Scotland), September 24, 2023.

Dogra, T., Pelz, L., Rüdiger, D., Kupke, S. Y., & Reichl, U.Reverse genetics for Influenza a virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccinationPresented at: Vir-AI-DIP Workshop Hamburg (Germany), July 18, 2023.

Kupke, S. Y., Dogra, T., Pelz, L., Hein, M. D., Ndeir, N., Rand, U., Boehme, J., Baelkner, M., Kershaw, O., Winkler, M., Cicin-Sain, L., Bruder, D., Pöhlmann, S., & Reichl, U.Influenza A virus defective interfering particles as antiviral agentsPresented at: 32^nd Annual Meeting of the Society for Virology (GfV)Ulm (Germany), March 28, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Hein, M. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivoPresented at: Cell Culture Engineering (CCE) XVIII Cancun (Mexico), April 23, 2023.

Pelz, L., Rüdiger, D., Dogra, T., Alnaji, F. D., Genzel, Y., Brooke, C. B., Kupke, S. Y., & Reichl, U.Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral TherapyPresented at: Vir-AI-DIP WorkshopHamburg (Germany), July 18, 2023.

Hein, M., Dogra, T., Arora , P., Rand , U., Genzel, Y., Cattaneo, M., Winkler, M., Cicin-Sain, L., Bruder, D., Schughart, K., Pöhlmann, S., Kupke, S. Y., & Reichl, U.Influenza A Virus-Derived Defective Interfering Particles for Antiviral TreatmentPresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.

Pelz, L., Rüdiger, D., Dogra, T., Alnaji, F. G., Genzel, Y., Brooke, C. B., Kupke, S. Y., & Reichl, U.Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral CandidatesPresented at: Vaccine Technology VIIISitges (Spain), June 12, 2022.

Pelz, L., Rüdiger, D., Dogra, T., Alnaji, F. G., Genzel, Y., Brooke, C. B., Kupke, S. Y., & Reichl, U.Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidatesPresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.

Pelz, L., Dogra, T., Rüdiger, D., Boehme, J., Kershaw, O., Bruder, D., Kupke, S. Y., & Reichl, U.Defective Interfering Particles of Influenza A Virus As Broad-Spectrum AntiviralsPresented at: 33^rd Annual Meeting of the Society for Virology (GfV)Vienna (Austria), March 25, 2023.

Dogra, T., Pelz, L., Rüdiger, D., Hein, M. D., Baelkner, M., Julia D. Boehme, J. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccinationPresented at: 32^nd Annual Meeting of the Society for Virology (GfV)Ulm (Germany), March 28, 2023.

Dogra, T., Pelz, L., Rüdiger, D., Hein, M. D., Baelkner, M., Julia D. Boehme, J. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccinationPresented at: 8^th European Congress of VirologyGdańsk (Poland), May 4, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Hein, M. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivoPresented at: Cell Culture Engineering (CCE) XVIII Cancun (Mexico), April 23, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Marichal-Gallardo, P., Hein, M. D., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo StudiesPresented at: Himmelfahrtstagung on Bioprocess Engineering 2023Weimar (Germany), May 15, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Marichal-Gallardo, P., Hein, M. D., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral EfficacyPresented at: 32^nd Annual Meeting of the Society for Virology (GFV)Ulm (Germany), March 25, 2023.

Dogra, T., Pelz, L., Marc, H., Rüdiger, D., Boehme, J., Bruder, D., Kupke, S. Y., & Reichl, U.Reverse genetics for Influenza A virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccinationPresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.